Pharma Marketing Network
DECEMBER 17, 2021
Big pharma has compelling reasons to change the way business gets done. With more than 75,000 companies in the EcoVadis network, the scorecard serves as a measurement with detailed insight into environmental, social, and ethical risks across 200 purchasing categories and 160 countries. What is Big Pharma doing to tackle climate change?
European Pharmaceutical Review
AUGUST 1, 2022
The joint Big Data Steering Group of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) has published a third workplan, setting actions to be delivered by 2025. According to EMA, the new plan will further enhance the efficient integration of data analysis into the regulatory evaluation of medicinal products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Leaders
MARCH 29, 2023
The European Medicines Agency (EMA) reported “remarkable” progress despite the pandemic in a mid-point assessment of its “Regulatory Science Strategy to 2025” to build a more adaptive regulatory system that will encourage innovation — including advances in clinical trials and a new real-world data (RWD) network.
pharmaphorum
NOVEMBER 1, 2022
billion by 2025, growing at a CAGR of 7.5%. Enhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech, Neuway Pharma and Ethris GmbH. LinkedIn: SAE Media Group Pharma. Who should attend: Directors of novel RNA therapies. BOOK BY 3OTH NOVEMBER AND SAVE £200.
pharmaphorum
JULY 22, 2022
Advances in Pharma 4.0 In 2025, the global cleanroom technology market is expected to reach nearly $5 billion. Sponsored by Ecolab, Elis Cleanroom, Innerspace, Microgenetics, Novatek. Co-Chaired by: Conor Murray, Chairman, Irish Cleanroom Society and Connor McMorrow, Aseptic Lead Cell Therapy, Takeda.
Pharmaceutical Technology
SEPTEMBER 2, 2022
According to analysis, of the 39 ‘blockbuster’ drugs (sales forecast >$1bn) expected to launch between 2021 and 2025, more than half could be from companies that have never launched a drug before. Often, pharma companies believe they have a higher level of control if they commercialise the product themselves,” says Estcourt. “It
pharmaphorum
OCTOBER 12, 2022
The move ties into an increasing willingness by the pharma industry to use AI to power its drug discovery and development efforts, and to reduce the time and costs involved in getting a new drug to market.
Expert insights. Personalized for you.
103 
Let's personalize your content